Royalty Pharma plc 4

EVP & CFO Terrance P. Coyne received 11,002 Class A Ordinary Shares via equity performance award settlement and had 18,500 Class E Ordinary Shares converted/reclassified into 18,500 Class A Ordinary Shares, all on an exempt basis.

On August 5, 2026, Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, received an exempt award of 11,002 Class A Ordinary Shares in connection with the settlement of Equity Performance Awards, increasing indirect holdings in an entity named TPC RP EPA1 LLC; in addition, various indirect holdings are reported, including shares held via his spouse’s IRA, his own IRA, and by his spouse directly. On August 7, 2026, 18,500 Class E Ordinary Shares were transferred (coded as “G”) into 18,500 Class A Ordinary Shares, reported as a change from direct Class E ownership to indirect Class A ownership, leaving the reporting person with 1,788,777 Class A Ordinary Shares held indirectly as noted in the filing, alongside a substantial additional economic interest through limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares. All transactions were reported as exempt under Rule 16b‑3 and represent equity compensation settlement and internal reclassification rather than open‑market purchases or sales.

Filing Facts

CIK

1802768

Ticker

RPRX

Form

4

Source Type

fda

Accession

0001814876-26-000025

Alert Tier

5